Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.

Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.

2.

Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.

Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.

Anticancer Res. 2017 Jan;37(1):125-134.

PMID:
28011482
3.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

4.

FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™).

Belikov S, Öberg C, Jääskeläinen T, Rahkama V, Palvimo JJ, Wrange Ö.

Mol Cell Endocrinol. 2013 Jan 5;365(1):95-107. doi: 10.1016/j.mce.2012.10.002. Epub 2012 Oct 11.

PMID:
23063623
5.

ARN-509: a novel antiandrogen for prostate cancer treatment.

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.

6.

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C.

J Biol Chem. 2013 Jul 5;288(27):19359-69. doi: 10.1074/jbc.M113.477216. Epub 2013 May 16.

7.

Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.

Bassetto M, Ferla S, Pertusati F, Kandil S, Westwell AD, Brancale A, McGuigan C.

Eur J Med Chem. 2016 Aug 8;118:230-43. doi: 10.1016/j.ejmech.2016.04.052. Epub 2016 Apr 22.

8.

Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.

Poutiainen PK, Huhtala T, Jääskeläinen T, Petsalo A, Küblbeck J, Kaikkonen S, Palvimo JJ, Raunio H, Närvänen A, Peräkylä M, Juvonen RO, Honkakoski P, Laatikainen R, Pulkkinen JT.

Mol Cell Endocrinol. 2014 Apr 25;387(1-2):8-18. doi: 10.1016/j.mce.2014.02.008. Epub 2014 Feb 22.

PMID:
24565895
9.

Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.

Hoang DT, Gu L, Liao Z, Shen F, Talati PG, Koptyra M, Tan SH, Ellsworth E, Gupta S, Montie H, Dagvadorj A, Savolainen S, Leiby B, Mirtti T, Merry DE, Nevalainen MT.

Mol Cancer Ther. 2015 Mar;14(3):713-26. doi: 10.1158/1535-7163.MCT-14-0819. Epub 2014 Dec 31.

10.

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.

Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.

Prostate. 2011 Sep;71(12):1344-56. doi: 10.1002/pros.21351. Epub 2011 Feb 9.

PMID:
21308717
11.

The development of Casodex (bicalutamide): preclinical studies.

Furr BJ.

Eur Urol. 1996;29 Suppl 2:83-95. Review.

PMID:
8717469
12.

Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.

Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O.

Cancer Res. 2005 Nov 1;65(21):9611-6.

13.

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC.

Clin Cancer Res. 2015 Sep 15;21(18):4133-42. doi: 10.1158/1078-0432.CCR-15-0269. Epub 2015 May 20.

14.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

O'Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W, Cork D, Davies BR, Wedge SR, Robson CN, Gaughan L.

Oncotarget. 2015 Sep 22;6(28):26029-40. doi: 10.18632/oncotarget.4347.

16.

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.

Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30.

PMID:
25634071
17.

Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.

Danquah M, Duke CB 3rd, Patil R, Miller DD, Mahato RI.

Pharm Res. 2012 Aug;29(8):2079-91. doi: 10.1007/s11095-012-0737-1. Epub 2012 Mar 27.

PMID:
22451249
18.

Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.

Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H, Dong Y.

Int J Cancer. 2013 Nov;133(9):2225-33. doi: 10.1002/ijc.28202. Epub 2013 May 9.

19.

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Jones D, Wade M, Nakjang S, Chaytor L, Grey J, Robson CN, Gaughan L.

Oncotarget. 2015 Oct 6;6(30):29782-94. doi: 10.18632/oncotarget.4927.

20.

The role of enzalutamide in the treatment of castration-resistant prostate cancer.

Rawlinson A, Mohammed A, Miller M, Kunkler R.

Future Oncol. 2012 Sep;8(9):1073-81. doi: 10.2217/fon.12.99. Review.

PMID:
23030482

Supplemental Content

Support Center